Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007011972) IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2007/011972 International Application No.: PCT/US2006/027937
Publication Date: 25.01.2007 International Filing Date: 19.07.2006
Chapter 2 Demand Filed: 23.07.2007
IPC:
A61K 9/14 (2006.01) ,A61K 9/16 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
14
Particulate form, e.g. powders
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
14
Particulate form, e.g. powders
16
Agglomerates; Granulates; Microbeadlets
Applicants:
INVERSEON, INC. [US/US]; 1701 Jackson Street, #102 San Francisco, CA 94109, US (AllExceptUS)
FRANKLIN, Amie, E. [US/US]; US (UsOnly)
FLASHNER, Michael [US/US]; US (UsOnly)
GARNER, William, J. [US/US]; US (UsOnly)
WURTMAN, David [US/US]; US (UsOnly)
BOND, Richard, A. [US/US]; US (UsOnly)
Inventors:
FRANKLIN, Amie, E.; US
FLASHNER, Michael; US
GARNER, William, J.; US
WURTMAN, David; US
BOND, Richard, A.; US
Agent:
CATALYST LAW GROUP, APC; Michael, B. Farber, Ph., D. Suite 170 9710 Scranton Road San Diego, CA 92121, US
Priority Data:
60/701,30419.07.2005US
Title (EN) IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES
(FR) PROFIL PHARMOCINETIQUE AMELIORE D'AGONISTES INVERSES BETA-ADRENERGIQUES POUR LE TRAITEMENT DE MALADIES DES VOIES AERIENNES PULMONAIRES
Abstract:
(EN) Methods for administering beta-adrenergic inverse agonists with improved pharmacokinetic profiles for the treatment of pulmonary airway diseases are disclosed. The beta adrenergic inverse agonists are formulated in a controlled- release formulation comprising: (1) a beta-adrenergic inverse agonist in a therapeutically effective quantity; and (2) at least one agent that controls release of the beta-adrenergic inverse agonist resulting in a pharmacokinetic profile that minimizes acute detrimental reduction in airway function with the first dose and with each successive dose. This pharmacokinetic profile typically results in slow release of the drug into the bloodstream resulting in a large average Tmax >4 hours. The controlled-release formulation may consist of multilayered matrix or erosional tablets, gastric-retention tablets, osmotic pump oral formulations, multiparticulate capsules or tablets or dermal patch.
(FR) L'invention concerne des procédés permettant d'administrer des agonistes inverses $g(b)-adrénergiques présentant des profils pharmacocinétiques pour traiter des maladies des voies aériennes pulmonaires. Ces agonistes sont formulés dans une formulation à libération régulée comprenant: (1) un agoniste inverse $g(b)-adrénergique en dose thérapeutiquement efficace; et (2) au moins un agent qui commande la libération de l'agoniste inverse $g(b)-adrénergique donnant lieu à un profil pharmacocinétique qui minimise une réduction préjudiciable aiguë au niveau de la fonction des voies aériennes avec la première dose et avec chaque dose successive. Le profil pharmacocinétique donne lieu d'ordinaire à une libération lente du médicament dans la circulation sanguine résultant en une grande moyenne Tmax>4 heures. La formulation à libération régulée peut consister en une matrice multicouche ou des comprimés d'érosion, des comprimés à rétention gastrique, des formulations orales à pompe osmotique, des capsules ou comprimés multiparticulaires ou des timbres dermiques.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
US20090214643AU2006269944